BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 03, 2011
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 9/30 cls
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Leerink Howard Liang Price target Market outperform -3% $64.06
Liang raised his target to $80 from $68 after FDA granted accelerated approval and EMA's CHMP issued a positive opinion recommending approval of Soliris eculizumab to treat atypical hemolytic uremic syndrome (aHUS) (see BioCentury, Sept. 26). He increased his 2011 and 2012 EPS estimates to $1.18 and $1.75, respectively, from $1.15 and $1.62. He also increased his 2011 and 2012 sales estimates to $746.1M and $1B, respectively, from $758.2M and $971.7M. Soliris, a humanized mAb targeting complement 5 (C5), is...

Read the full 675 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >